{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:11:41Z","timestamp":1790734301364,"version":"4.1.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1097\/ico.0b013e3181ca2ba3","type":"journal-article","created":{"date-parts":[[2010,5,20]],"date-time":"2010-05-20T02:33:36Z","timestamp":1274322816000},"page":"751-757","source":"Crossref","is-referenced-by-count":57,"title":["Randomized Clinical Study for Comparative Evaluation of Fourth-Generation Fluoroquinolones With the Combination of Fortified Antibiotics in the Treatment of Bacterial Corneal Ulcers"],"prefix":"10.1097","volume":"29","author":[{"given":"Vinit Mahendra","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Tandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gita","family":"Satpathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niranjan","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavna","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushar","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeewan S","family":"Titiyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasik B","family":"Vajpayee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-7-20210204","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/bjo.82.2.137","article-title":"Antimicrobial management of presumed microbial keratitis: guidelines for treatment of central and peripheral ulcers.","volume":"82","author":"Bennett","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"R3-7-20210204","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1001\/archopht.1993.01090090062020","article-title":"Ciprofloxacin 0.3% ophthalmic ointment in the treatment of bacterial keratitis. The Ciprofloxacin Ointment Bacterial Keratitis Study Group.","volume":"111","author":"Wilhelmus","year":"1993","journal-title":"Arch Ophthalmol"},{"key":"R4-7-20210204","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0002-9394(14)74449-6","article-title":"Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of ulcerative keratitis.","volume":"115","author":"Parks","year":"1993","journal-title":"Am J Ophthalmol"},{"key":"R5-7-20210204","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/archopht.1995.01100100045026","article-title":"Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group.","volume":"113","author":"OBrien","year":"1995","journal-title":"Arch Ophthalmol"},{"key":"R6-7-20210204","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0039-6257(79)90128-0","article-title":"Initial therapy of suspected microbial corneal ulcers. II. Specific antibiotic therapy based on corneal smears.","volume":"24","author":"Jones","year":"1979","journal-title":"Surv Ophthalmol"},{"key":"R7-7-20210204","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0039-6257(87)90103-2","article-title":"Tobramycin in ophthalmology.","volume":"32","author":"Wilhelmus","year":"1987","journal-title":"Surv Ophthalmol"},{"key":"R8-7-20210204","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/S0161-6420(96)30416-8","article-title":"Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group.","volume":"103","author":"Hyndiuk","year":"1966","journal-title":"Ophthalmology"},{"key":"R9-7-20210204","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1136\/bjo.84.4.378","article-title":"Fluoroquinolone and fortified antibiotics for treating bacterial corneal ulcers.","volume":"84","author":"Gangopadhyay","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"R10-7-20210204","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00003226-200103000-00013","article-title":"Bacteriologic and clinical efficacy of ofloxacin 3% versus ciprofloxacin 0.3% ophthalmic solutions in the treatment of patients with culture-positive bacterial keratitis.","volume":"20","author":"Prajna","year":"2001","journal-title":"Cornea"},{"key":"R11-7-20210204","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0002-9394(14)74467-8","article-title":"Ciprofloxacin-resistant bacterial keratitis.","volume":"115","author":"Maffett","year":"1993","journal-title":"Am J Ophthalmol"},{"key":"R12-7-20210204","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0161-6420(99)90008-8","article-title":"In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin. Emerging resistance.","volume":"106","author":"Kunimoto","year":"1999","journal-title":"Ophthalmology"},{"key":"R13-7-20210204","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0161-6420(99)00716-2","article-title":"Emerging f1uoroquinolone resistance in bacterial keratitis: a 5-year review.","volume":"106","author":"Goldstein","year":"1999","journal-title":"Ophthalmology"},{"key":"R14-7-20210204","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.survophthal.2004.01.005","article-title":"Fluoroquinolones: mechanism of action, classification, and development of resistance.","volume":"49","author":"Blondeau","year":"2004","journal-title":"Surv Ophthalmol"},{"key":"R15-7-20210204","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.survophthal.2005.06.002","article-title":"In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone.","volume":"50","author":"Stroman","year":"2005","journal-title":"Surv Ophthalmol"},{"key":"R16-7-20210204","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.survophthal.2005.07.001","article-title":"Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans.","volume":"50","author":"Robertson","year":"2005","journal-title":"Surv Ophthalmol"},{"key":"R17-7-20210204","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.survophthal.2005.05.004","article-title":"Clinical safety of moxifloxacin ophthalmic solution 0.5% (VIGAMOX) in pediatric and non-pediatric patients with bacterial conjunctivitis.","volume":"50","author":"Silver","year":"2005","journal-title":"Surv Ophthalmol"},{"key":"R18-7-20210204","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ajo.2006.05.044","article-title":"Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin.","volume":"142","author":"Deramo","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R19-7-20210204","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1089\/jop.2005.21.36","article-title":"Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits.","volume":"21","author":"Jensen","year":"2005","journal-title":"J Ocul Pharmacol Ther"},{"key":"R20-7-20210204","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1128\/AAC.48.6.1948-1952.2004","article-title":"Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis.","volume":"48","author":"Dajcs","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R21-7-20210204","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ajo.2005.08.081","article-title":"Comparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitis.","volume":"141","author":"Parmar","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R22-7-20210204","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/ajcp\/45.4_ts.493","article-title":"Antibiotic susceptibility-testing by standardized disc method.","volume":"45","author":"Bauer","year":"1966","journal-title":"Am J Clin Pathol"},{"key":"R23-7-20210204","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/bjo.85.7.842","article-title":"Bacterial keratitis: a prospective clinical and microbiological study.","volume":"85","author":"Schaefer","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"R24-7-20210204","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1136\/bjo.87.7.834","article-title":"Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases.","volume":"87","author":"Bourcier","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"R25-7-20210204","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/ICO.0b013e318156caf2","article-title":"Risk factors and causative organisms in microbial keratitis.","volume":"27","author":"Green","year":"2008","journal-title":"Cornea"},{"key":"R26-7-20210204","first-page":"1622","article-title":"Epidemiology of bacterial keratitis in a referral centre in south India.","volume":"114","author":"Bharathi","year":"2003","journal-title":"Indian J Med Microbiol"},{"key":"R27-7-20210204","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1136\/bjo.81.11.965","article-title":"Epidemiology and aetiological diagnosis of corneal ulceration in Madurai, south India.","volume":"81","author":"Srinivasan","year":"1997","journal-title":"Br J Ophthalmol"},{"key":"R28-7-20210204","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0002-9394(14)76903-X","article-title":"Epidemiologic characteristics, predisposing factors, and etiologic diagnosis of corneal ulceration in Nepal.","volume":"111","author":"Upadhyay","year":"1991","journal-title":"Am J Ophthalmol"},{"key":"R29-7-20210204","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.ophtha.2006.12.011","article-title":"Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial.","volume":"114","author":"Constantinou","year":"2007","journal-title":"Ophthalmology"},{"key":"R30-7-20210204","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.jcrs.2007.04.015","article-title":"Fourth generation fluoroquinolones resistant bacterial keratitis.","volume":"33","author":"Jhanji","year":"2007","journal-title":"J Cataract Refract Surg"},{"key":"R31-7-20210204","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ophtha.2004.09.029","article-title":"Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor.","volume":"112","author":"Solomon","year":"2005","journal-title":"Ophthalmology"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/ICO.0b013e3181ca2ba3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:21:33Z","timestamp":1786040493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00003226-201007000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e3181ca2ba3","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}